Lack of regression of left ventricular hypertrophy is associated with higher incidence of revascularization in hypertension: The LIFE Study

References

• Kannel WB, Gordon T, Castelli WP, Margolis JR. Electrocardiographic left ventricular hypertrophy and risk of coronary heart disease. The Framingham study. Ann Intern Med. 1970;72:813–822.
   PubMedGoogle Scholar
• Koren MJ, Devereux RB, Casale PN, Savage DD, Laragh JH. Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Ann Intern Med. 1991;114:345–352.
   PubMed Web of Science ®Google Scholar
• Verdecchia P, Schillaci G, Borgioni C, Ciucci A, Gattobigio R, Zampi I, . Prognostic significance of serial changes in left ventricular mass in essential hypertension. Circulation. 1998;97:48–54.
   PubMed Web of Science ®Google Scholar
• Friehs I, del Nido PJ. Increased susceptibility of hypertrophied hearts to ischemic injury. Ann Thorac Surg. 2003; 75:S678–S684.
   PubMed Web of Science ®Google Scholar
• Mehta SK, Rame JE, Khera A, Murphy SA, Canham RM, Peshock RM, . Left ventricular hypertrophy, subclinical atherosclerosis, and inflammation. Hypertension. 2007;49: 1385–1391.
   PubMed Web of Science ®Google Scholar
• Roman MJ, Pickering TG, Schwartz JE, Pini R, Devereux RB. Association of carotid atherosclerosis and left ventricular hypertrophy. J Am Coll Cardiol. 1995;25:83–90.
   PubMed Web of Science ®Google Scholar
• Wachtell K, Okin PM, Olsen MH, Dahlöf B, Devereux RB, Ibsen H, . Regression of electrocardiographic left ventricular hypertrophy during antihypertensive therapy and reduction in sudden cardiac death: The LIFE Study. Circulation. 2007;116:700–705.
   PubMed Web of Science ®Google Scholar
• Okin PM, Devereux RB, Jern S, Kjeldsen SE, Julius S, Nieminen MS, . Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events. JAMA. 2004;292:2343–2349.
   PubMed Web of Science ®Google Scholar
• Wachtell K, Palmieri V, Olsen MH, Bella JN, Aalto T, Dahlöf B, . Urine albumin/creatinine ratio and echocardiographic left ventricular structure and function in hypertensive patients with electrocardiographic left ventricular hypertrophy: The LIFE study. Losartan Intervention for Endpoint Reduction. Am Heart J. 2002;143:319–326.
   PubMed Web of Science ®Google Scholar
• Lieb W, Mayer B, Stritzke J, Doering A, Hense HW, Loewel H, . Association of low-grade urinary albumin excretion with left ventricular hypertrophy in the general population: The MONICA/KORA Augsburg Echocardiographic Substudy. Nephrol Dial Transplant. 2006;21:2780–2787.
   PubMed Web of Science ®Google Scholar
• Furtner M, Kiechl S, Mair A, Seppi K, Weger S, Oberhollenzer F, . Urinary albumin excretion is independently associated with carotid and femoral artery atherosclerosis in the general population. Eur Heart J. 2005;26:279–287.
   PubMed Web of Science ®Google Scholar
• Bigazzi R, Bianchi S, Nenci R, Baldari D, Baldari G, Campese VM. Increased thickness of the carotid artery in patients with essential hypertension and microalbuminuria. J Hum Hypertens. 1995;9:827–833.
   PubMed Web of Science ®Google Scholar
• Cottone S, Mulé G, Nardi E, Lorito MC, Guarneri M, Arsena R, . Microalbuminuria and early endothelial activation in essential hypertension. J Hum Hypertens. 2007;21:167–172.
   PubMed Web of Science ®Google Scholar
• Olsen MH, Wachtell K, Dahlöf B, Devereux RB, Ibsen H, Kjeldsen SE, . The effect of losartan compared with atenolol on the incidence of revascularization in patients with hypertension and electrocardiographic left ventricular hypertrophy. The LIFE study. J Hum Hypertens. 2006;20:460–464.
   PubMed Web of Science ®Google Scholar
• Dahlöf B, Devereux R, de Faire U, Fyhrquist F, Hedner T, Ibsen H, . The Losartan Intervention For Endpoint reduction (LIFE) in Hypertension study: Rationale, design, and methods. The LIFE Study Group. Am J Hypertens. 1997;10:705–713.
   PubMed Web of Science ®Google Scholar
• Anderson KM, Wilson PW, Odell PM, Kannel WB. An updated coronary risk profile. A statement for health professionals. Circulation. 1991;83:356–362.
   PubMed Web of Science ®Google Scholar
• Sukhija R, Aronow WS, Kakar P, Garza L, Sachdeva R, Sinha A, . Relation of microalbuminuria and coronary artery disease in patients with and without diabetes mellitus. Am J Cardiol. 2006;98:279–281.
   PubMed Web of Science ®Google Scholar
• Tuttle KR, Puhlman ME, Cooney SK, Short R. Urinary albumin and insulin as predictors of coronary artery disease: An angiographic study. Am J Kidney Dis. 1999;34:918–925.
   PubMed Web of Science ®Google Scholar
• Stuveling EM, Hillege HL, Bakker SJ, Asselbergs FW, de Jong PE, Gans RO, . C-reactive protein and microalbuminuria differ in their associations with various domains of vascular disease. Atherosclerosis. 2004;172:107–114.
   PubMed Web of Science ®Google Scholar
• Okin PM, Devereux RB, Jern S, Kjeldsen SE, Julius S, Dahlöf B. Baseline characteristics in relation to electrocardiographic left ventricular hypertrophy in hypertensive patients: The Losartan intervention for endpoint reduction (LIFE) in hypertension study. The Life Study Investigators. Hypertension. 2000;36:766–773.
   PubMed Web of Science ®Google Scholar
• Hammond IW, Devereux RB, Alderman MH, Laragh JH. Relation of blood pressure and body build to left ventricular mass in normotensive and hypertensive employed adults. J Am Coll Cardiol. 1988;12:996–1004.
   PubMed Web of Science ®Google Scholar
• Liebson PR, Grandits GA, Dianzumba S, Prineas RJ, Grimm RH, Jr., Neaton JD, . Comparison of five antihypertensive monotherapies and placebo for change in left ventricular mass in patients receiving nutritional-hygienic therapy in the Treatment of Mild Hypertension Study (TOMHS). Circulation. 1995;91:698–706.
   PubMed Web of Science ®Google Scholar
• Schillaci G, Pasqualini L, Vaudo G, Lupattelli G, Pirro M, Gemelli F, . Effect of body weight changes on 24-hour blood pressure and left ventricular mass in hypertension: A 4-year follow-up. Am J Hypertens. 2003;16:634–639.
   PubMedGoogle Scholar
• Strawn WB, Chappell MC, Dean RH, Kivlighn S, Ferrario CM. Inhibition of early atherogenesis by losartan in monkeys with diet-induced hypercholesterolemia. Circulation. 2000; 101:1586–1593.
   PubMed Web of Science ®Google Scholar
• Takai S, Jin D, Sakaguchi M, Muramatsu M, Miyazaki M. The regressive effect of an angiotensin II receptor blocker on formed fatty streaks in monkeys fed a high-cholesterol diet. J Hypertens. 2005;23:1879–1886.
   PubMed Web of Science ®Google Scholar
• Lin CL, Hsu PY, Yang CT, Yang HY, Yang TY, Huang WH, . LV mass index significantly impacts on patient and renal outcomes in patients with coronary artery bypass grafting and poor left-ventricular function. Ren Fail. 2003;25:287–295.
   PubMed Web of Science ®Google Scholar
• Christenson JT, Simonet F, Schmuziger M. The impact of arterial hypertension on the results of coronary artery bypass grafting. Thorac Cardiovasc Surgeon. 1996;44:126–31.
   PubMed Web of Science ®Google Scholar
• Toumpoulis IK, Chamogeorgakis TP, Angouras DC, Swistel DG, Anagnostopoulos CE, Rokkas CK. The impact of left ventricular hypertrophy on early and long-term survival after coronary artery bypass grafting. Int J Cardiol. 2009;135: 36–42.
   PubMed Web of Science ®Google Scholar
• Lauer MS, Martino D, Ishwaran H, Blackstone EH. Quantitative measures of electrocardiographic left ventricular mass, conduction, and repolarization, and long-term survival after coronary artery bypass grafting. Circulation. 2007;116:888–893.
   PubMed Web of Science ®Google Scholar
• Eshøj O, Feldt-Rasmussen B, Larsen ML, Mogensen EF. Comparison of overnight, morning and 24-hour urine collections in the assessment of diabetic microalbuminuria. Diabet Med. 1987;4:531–533.
   PubMed Web of Science ®Google Scholar